During the recent session, Gilead Sciences, Inc. (NASDAQ:GILD)’s traded shares were 1,977,158, with the beta value of the company hitting 0.41. At the last check, the stock’s price was $65.54, reflecting an intraday loss of -0.09% or -$0.06. The 52-week high for the GILD share is $85.79, that puts it down -30.9% from that peak though still a striking +13.7% gain since the share price plummeted to a 52-week low of $56.56. The company’s market capitalization is $82.48 Billion, and the average intraday trading volume over the past 10 days was 8.21 Million shares, and the average trade volume was 8.65 Million shares over the past three months.
Gilead Sciences, Inc. (GILD) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2.3. GILD has a Sell rating from 2 analyst(s) out of 32 analysts who have looked at this stock. 14 analyst(s) recommend to Hold the stock while 2 suggest Overweight, and 14 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $2.03.
Gilead Sciences, Inc. (NASDAQ:GILD): Trading Information
Gilead Sciences, Inc. (GILD) registered a -0.09% downside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.64% in intraday trading to $66.84 this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is 1.73%, and it has moved by 1.54% in 30 days. Based on these gigs, the overall price performance for the year is 12.85%. The short interest in Gilead Sciences, Inc. (NASDAQ:GILD) is 22.52 Million shares and it means that shorts have 2.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $74.38, which implies an increase of 13.49% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $60 and $100 respectively. As a result, GILD is trading at a discount of 52.58% off the target high and -8.45% off the low.
Gilead Sciences, Inc. (GILD) projections and forecasts
Statistics show that Gilead Sciences, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Gilead Sciences, Inc. (GILD) shares have gone up +3.14% during the last six months, with a year-to-date growth rate less than the industry average at 1.69% against 8.4%. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 20.8% this quarter and then jump 58.6% in the quarter after that. In the rating firms’ projections, revenue will increase 0.5% compared to the previous financial year.
Revenue for the current quarter is expected to be $6.7 Billion as predicted by 19 analyst(s). Meanwhile, a consensus of 19 analyst(s) estimates revenue growth to $6.16 Billion by the end of June 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarter totaled $5.55 Billion. In this case, analysts expect current quarter sales to grow by 20.8%.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -61.8%. While earnings are projected to return -97.7% in 2021, the next five years will return 3.26% per annum.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
GILD Dividend Yield
Gilead Sciences, Inc. is due to release its next quarterly earnings between April 28 and May 03, 2021. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Gilead Sciences, Inc. is 2.84, with the dividend yield indicating at 4.33 percent, continuing the trend of increasing dividends in recent years. The average dividend yield of the company for the last 5 years is 3.19%.
Gilead Sciences, Inc. (NASDAQ:GILD)’s Biggest Investors
Gilead Sciences, Inc. insiders own 0.09% of total outstanding shares while institutional holders control 79.38%, with the float percentage being 79.45%. Capital Research Global Investors is the largest shareholder of the company, while 2159 institutions own stock in it. As of Dec 30, 2020, the company held over 121.67 Million shares (or 9.66% of all shares), a total value of $7.09 Billion in shares.
The next largest institutional holding, with 111.18 Million shares, is of Blackrock Inc.’s that is approximately 8.83% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $6.48 Billion.
Also, the Mutual Funds coming in first place with the largest holdings of Gilead Sciences, Inc. (GILD) shares are Vanguard Total Stock Market Index Fund and American Mutual Fund Inc. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 35,347,893 shares. This amounts to just over 2.81 percent of the company’s overall shares, with a $2.06 Billion market value. The same data shows that the other fund manager holds slightly less at 31.91 Million, or about 2.53% of the stock, which is worth about $2.09 Billion.